{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:28Z","timestamp":1792803148799,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":557,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["777204"],"award-info":[{"award-number":["777204"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["777204"],"award-info":[{"award-number":["777204"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM). The aim of this study was to evaluate the effect of sacubitril\/valsartan on peak oxygen consumption (VO2) in patients with non-obstructive HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This is a phase II, randomized, open-label multicentre study that enrolled adult patients with symptomatic non-obstructive HCM (New York Heart Association class I\u2013III) who were randomly assigned (2:1) to receive sacubitril\/valsartan (target dose 97\/103\u2009mg) or control for 16\u2009weeks. The primary endpoint was a change in peak VO2. Secondary endpoints included echocardiographic measures of cardiac structure and function, natriuretic peptides and other cardiac biomarkers, and Minnesota Living with Heart Failure quality of life. Between May 2018 and October 2021, 354 patients were screened for eligibility, 115 patients (mean age 58\u2009years, 37% female) met the study inclusion criteria and were randomly assigned to sacubitril\/valsartan (n\u2009=\u200979) or control (n\u2009=\u200936). At 16\u2009weeks, there was no significant change in peak VO2 from baseline in the sacubitril\/valsartan (15.3 [4.3] vs. 15.9 [4.3] ml\/kg\/min, p\u2009=\u20090.13) or control group (p\u2009=\u20090.47). No clinically significant changes were found in blood pressure, cardiac structure and function, plasma biomarkers, or quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with HCM, a 16-week treatment with sacubitril\/valsartan was well tolerated but had no effect on exercise capacity, cardiac structure, or function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3291","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T05:18:22Z","timestamp":1716787102000},"page":"1361-1368","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Sacubitril\/Valsartan for the Treatment of Non-Obstructive Hypertrophic Cardiomyopathy: An Open Label Randomized Controlled Trial (SILICOFCM)"],"prefix":"10.1093","volume":"26","author":[{"given":"Lazar","family":"Velicki","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad ,","place":["Serbia"]},{"name":"Institute of Cardiovascular Diseases of Vojvodina , Sremska Kamenica ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejana","family":"Popovic","sequence":"additional","affiliation":[{"name":"Cardiology Department, Faculties of Medicine and Pharmacy, University of Belgrade \u00a0","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-2538","authenticated-orcid":false,"given":"Nduka C.","family":"Okwose","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Translational and Clinical Research and Biosciences Institute, Faculty of Medical Sciences, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Faculty of Health and Life Science, Coventry University , Coventry ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Preveden","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad ,","place":["Serbia"]},{"name":"Institute of Cardiovascular Diseases of Vojvodina , Sremska Kamenica ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milorad","family":"Tesic","sequence":"additional","affiliation":[{"name":"Cardiology Department, Faculties of Medicine and Pharmacy, University of Belgrade \u00a0","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tafelmeier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Medical Centre Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Charman","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Translational and Clinical Research and Biosciences Institute, Faculty of Medical Sciences, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barlocco","sequence":"additional","affiliation":[{"name":"Careggi University Hospital, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.","family":"MacGowan","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Translational and Clinical Research and Biosciences Institute, Faculty of Medical Sciences, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar M.","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Cardiology Department, Faculties of Medicine and Pharmacy, University of Belgrade \u00a0","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Filipovic","sequence":"additional","affiliation":[{"name":"Bioengineering Research and Development Center, BioIRC , Kragujevac ,","place":["Serbia"]},{"name":"Faculty of Engineering, University of Kragujevac , Kragujevac ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Ristic","sequence":"additional","affiliation":[{"name":"Cardiology Department, Faculties of Medicine and Pharmacy, University of Belgrade \u00a0","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Careggi University Hospital, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars S.","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Medical Centre Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-6542","authenticated-orcid":false,"given":"Djordje G.","family":"Jakovljevic","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Translational and Clinical Research and Biosciences Institute, Faculty of Medical Sciences, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Faculty of Health and Life Science, Coventry University , Coventry ,","place":["UK"]},{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SILICOFCM Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2026010913052589700_ejhf3291-bib-0001","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"3291","journal-title":"Circ Res"},{"key":"2026010913052589700_ejhf3291-bib-0002","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","article-title":"Genetic pathogenesis of hypertrophic and dilated cardiomyopathy","volume":"14","author":"Garfinkel","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2026010913052589700_ejhf3291-bib-0004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev-med-042220-021539","article-title":"Hypertrophic cardiomyopathy: New concepts and therapies","volume":"73","author":"Maron","year":"2022","journal-title":"Annu Rev Med"},{"key":"2026010913052589700_ejhf3291-bib-0006","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026010913052589700_ejhf3291-bib-0007","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: A randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"2026010913052589700_ejhf3291-bib-0008","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Zamorano","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010913052589700_ejhf3291-bib-0009","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913052589700_ejhf3291-bib-0011","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026010913052589700_ejhf3291-bib-0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733475","article-title":"Impact of sacubitril\/valsartan on clinical and echocardiographic parameters in heart failure patients with reduced ejection fraction: Data from a real life 2-year follow-up study","volume":"12","author":"Armentaro","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026010913052589700_ejhf3291-bib-0013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ehf2.13691","article-title":"Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure","volume":"9","author":"Sun","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0014","article-title":"Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction","volume":"31","author":"Landolfo","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026010913052589700_ejhf3291-bib-0015","doi-asserted-by":"crossref","first-page":"A2665 (abstr)","DOI":"10.1016\/S0735-1097(18)33206-6","article-title":"The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril\/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial)","volume":"71","author":"Biering-Sorensen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2017.10.074","article-title":"Sacubitril\/valsartan and short-term changes in the 6-minute walk test: A pilot study","volume":"252","author":"Beltr\u00e1n","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0017","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/clc.23346","article-title":"Design of the SILICOFCM study: Effect of sacubitril\/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy","volume":"43","author":"Tafelmeier","year":"2020","journal-title":"Clin Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026010913052589700_ejhf3291-bib-0019","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1161\/CIR.0000000000000406","article-title":"2016 Focused update: Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations","volume":"133","author":"Guazzi","year":"2016","journal-title":"Circulation"},{"key":"2026010913052589700_ejhf3291-bib-0020","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy a randomized clinical trial","volume":"317","author":"Saberi","year":"3291","journal-title":"JAMA"},{"key":"2026010913052589700_ejhf3291-bib-0021","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00362-017-0925-5","article-title":"Martin Bland (2015): An introduction to medical statistics","volume":"58","author":"Xu","year":"3291","journal-title":"Stat Papers"},{"key":"2026010913052589700_ejhf3291-bib-0022","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0023","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jchf.2014.11.011","article-title":"Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: A potential role for comprehensive noninvasive hemodynamic assessment","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0024","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: Exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010913052589700_ejhf3291-bib-0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/heart.87.3.247","article-title":"Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity","volume":"87","author":"Matsumura","year":"2002","journal-title":"Heart"},{"key":"2026010913052589700_ejhf3291-bib-0026","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"2026010913052589700_ejhf3291-bib-0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/00015385.2019.1669317","article-title":"Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test","volume":"75","author":"Malfatto","year":"2020","journal-title":"Acta Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0028","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"2026010913052589700_ejhf3291-bib-0029","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2021.05.005","article-title":"Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study","volume":"239","author":"Dos Santos","year":"2021","journal-title":"Am Heart J"},{"key":"2026010913052589700_ejhf3291-bib-0031","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00015385.2018.1521054","article-title":"Effects of sacubitril\/valsartan on functional status and exercise capacity in real-world patients","volume":"74","author":"Lau","year":"2019","journal-title":"Acta Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy \u2013 a randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"2026010913052589700_ejhf3291-bib-0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026010913052589700_ejhf3291-bib-0034","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy","volume":"96","author":"Araujo","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.48.715","article-title":"A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker","volume":"48","author":"Yamazaki","year":"2007","journal-title":"Int Heart J"},{"key":"2026010913052589700_ejhf3291-bib-0036","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: A pilot, randomized study","volume":"11","author":"Penicka","year":"2009","journal-title":"J Mol Diagn"},{"key":"2026010913052589700_ejhf3291-bib-0037","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1172\/JCI200214677","article-title":"The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model","volume":"109","author":"Semsarian","year":"2002","journal-title":"J Clin Invest"},{"key":"2026010913052589700_ejhf3291-bib-0038","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1172\/JCI42028","article-title":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2","volume":"120","author":"Teekakirikul","year":"2010","journal-title":"J Clin Invest"},{"key":"2026010913052589700_ejhf3291-bib-0039","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010913052589700_ejhf3291-bib-0040","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913052589700_ejhf3291-bib-0041","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12872-022-02829-w","article-title":"Haemodynamic determinants of quality of life in chronic heart failure","volume":"22","author":"Fatrin","year":"2022","journal-title":"BMC Cardiovasc Disord"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1361\/65512008\/eurjhf_26_6_1361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1361\/65512008\/eurjhf_26_6_1361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:30Z","timestamp":1767981990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/6\/1361\/8328681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,27]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3291","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"2023-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}